Capricor Therapeutics To Present Long-Term Data From HOPE-2 Open Label Extension Study At 2024 World Muscle Society Congress October 8-12, 2024
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics will present long-term data from its HOPE-2 open-label extension study at the 2024 World Muscle Society Congress. The study focuses on the safety and efficacy of deramiocel for treating Duchenne muscular dystrophy.
October 04, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics is set to present promising long-term data on its lead asset, deramiocel, for Duchenne muscular dystrophy at the WMS 2024. This could positively influence investor sentiment and CAPR's stock price.
The presentation of long-term safety and efficacy data for deramiocel at a major congress could enhance Capricor's reputation and investor confidence, potentially leading to a positive impact on CAPR's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100